Myelodysplastic Syndrome Clinical Trial
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Summary
This is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product in a parent clinical study.
After completing a parent clinical study (approximately 2 years), eligible participants will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.
Eligibility Criteria
Inclusion Criteria:
Provision of written informed consent for this study by the participant or participant's parent(s)/ legal guardian(s) and written informed assent by participant, if applicable
Have received Lenti-D Drug Product in a parent clinical study
Able to comply with study requirements
Exclusion Criteria:
There are no exclusion criteria for this Study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Los Angeles California, 90095, United States
Palo Alto California, 94304, United States
Boston Massachusetts, 02115, United States
Minneapolis Minnesota, 55455, United States
Caba , , Argentina
North Adelaide , , Australia
São Paulo , 05403, Brazil
Le Kremlin-Bicêtre Cedex, 94275, France
Leipzig , 04103, Germany
Utrecht , 3584, Netherlands
London , , United Kingdom
How clear is this clinincal trial information?